Table 3 Lung cancer risk of antihypertensive groups and combination of aspirin groups at different follow-up time points*
Exposure of Aspirin | End of 2006 | End of 2009 | End of 2013 | ||||||
|---|---|---|---|---|---|---|---|---|---|
< 7 years | < 10 years | < 14 years | |||||||
HR | 95% CI | p | HR | 95% CI | p | HR | 95% CI | p | |
All Anti-hypertensives | |||||||||
Aspirin: NO | 0.57 | 0.53–0.60 | < 0.001 | 0.60 | 0.57–0.63 | < 0.001 | 0.63 | 0.60–0.66 | < 0.001 |
Aspirin: YES | 0.46 | 0.42–0.50 | < 0.001 | 0.56 | 0.52–0.60 | < 0.001 | 0.64 | 0.60–0.68 | < 0.001 |
ACEi/ARB | |||||||||
Aspirin: NO | 0.55 | 0.36–0.83 | 0.005 | 0.53 | 0.36–0.79 | 0.001 | 0.45 | 0.32–0.62 | < 0.001 |
Aspirin: YES | 0.63 | 0.38–1.02 | 0.060 | 0.67 | 0.44–1.01 | 0.055 | 0.71 | 0.48–1.05 | 0.090 |
α-blocker | |||||||||
Aspirin: NO | 0.70 | 0.57–0.86 | < 0.001 | 0.68 | 0.55–0.84 | < 0.001 | 0.61 | 0.48–0.77 | < 0.001 |
Aspirin: YES | 0.43 | 0.24–0.78 | 0.005 | 0.41 | 0.25–0.69 | < 0.001 | 0.53 | 0.34–0.84 | 0.007 |
β-blocker | |||||||||
Aspirin: NO | 0.98 | 0.76–1.26 | 0.879 | 0.90 | 0.72–1.11 | 0.326 | 0.79 | 0.65–0.96 | 0.017 |
Aspirin: YES | 0.87 | 0.61–1.22 | 0.407 | 0.76 | 0.56–1.03 | 0.074 | 0.81 | 0.62–1.05 | 0.115 |
CCB | |||||||||
Aspirin: NO | 1.05 | 0.87–1.27 | 0.608 | 1.02 | 0.86–1.21 | 0.808 | 0.89 | 0.73–1.08 | 0.222 |
Aspirin: YES | 0.67 | 0.48–0.94 | 0.021 | 0.79 | 0.60–1.04 | 0.093 | 0.82 | 0.64–1.06 | 0.129 |